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Abstract Although many treatments have been applied to
treat hormone-refractory prostate cancer (HRPC), thera-
peutic outcome is not altogether satisfactory. In the case of
locally recurring HRPC, uncontrolled gross hematuria,
dysuria, and scalding are often experienced. We report a
patient who improved following intra-arterial infusion of
cisplatin (CDDP) and ifosfamide (IFM) to treat urinary
retention caused by locally recurring HRPC. After che-
motherapy, cancer volume was remarkably reduced and
symptoms improved.
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Introduction
It is well known that most prostatic carcinomas are
androgen dependent. Therefore, androgen deprivation
therapy (ADT) is one of most effective systemic palliative
treatments for such carcinomas. Although ADT is initially
extremely effective, serum prostate-speciﬁc antigen (PSA)
levels increase over time, and the disease eventually
becomes characteristic of hormone-refractory prostate
cancer (HRPC). Several types of treatment have been
applied to treat HRPC, including antiandrogen alternation
[1], supplemental steroid therapy [2], and generalized
chemotherapy with docetaxel hydrate (DTX) [3, 4]. How-
ever, these therapeutic modalities have only a short-term
effect. In addition, HRPC is occasionally encountered with
locally recurring carcinoma and uncontrolled gross hema-
turia, dysuria, and scalding. These symptoms adversely
affect the quality of life of HRPC patients. We report
a patient with HRPC with locally recurring HRPC
accompanied by urinary retention. Treatment with intra-
arterial infusion chemotherapy using cisplatin (CDDP) and
ifosfamide (IFM) removed the symptom for a considerable
period.
Case reports
A 64-year-old Japanese man was admitted to hospital with
lower urinary tract symptom (LUTS) and a high PSA level
(180 ng/ml) in April 1997. He was diagnosed with pros-
tate cancer (moderately differentiated adenocarcinoma,
T3bN1M0, stage D1) and was started on combined andro-
gen blockade (CAB) with leuprorelin acetate (11.25 mg/
3 months) and ﬂutamide (375 mg/day). Two months later,
ﬂutamide was discontinued because of liver damage, and
treatment was switched to estramustine phosphate (EMP)
sodium (626.8 mg/day). Six months after starting hormonal
therapy, metastatic lymph node lesion and seminal vessel
invasion was no longer visible on computed tomography
(CT). Therefore, we performed radical prostatectomy
(moderately differentiated adenocarcinoma, Gleason score
4 ? 3 = 7, ly?, v?, pn?, sv-, pw-, dw-, cap?, n?) and
obturator lymph node excision to completely remove the
cancerous lesion. The patient received adjuvant radia-
tion therapy (60 Gy) to the pelvic cavity postoperatively
because pathological ﬁndings showed the prostatic carci-
noma had extended beyond the prostate capsule. Addition-
ally, a course of chemotherapy with cyclophosphamide
(CPM), doxorubicin hydrochloride (ADM), and CDDP
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(CPM 500 mg, ADM 50 mg, CDDP 100 mg) was performed.
Thereafter, the patient was followed up with hormonal
therapy consisting of leuprorelin acetate (11.25 mg/
3 months) and EMP (626.8 mg/day). In June 2002, PSA
value decrease 1.35 ng/ml. However, PSA value continued
to increase (13.74 ng/ml) in December 2004; magnetic
resonance imaging (MRI, Fig. 1) and transrectal ultraso-
nography (TRUS) revealed abnormal ﬁndings in the anas-
tomotic area. Transrectal biopsy was performed, and we
diagnosed a recurrence of prostatic carcinoma (moderately
differentiated adenocarcinoma, Gleasen score, 4 ? 4 = 8).
The patient complained of dysuria that eventually pro-
gressed to urinary retention. Whole-body CT and bone
scintigraphy showed no abnormal ﬁndings. As a result, the
ﬁnal diagnosis was HRPC with local recurrence.
We then decided to attempt intra-arterial infusion che-
motherapy to treat the local recurrence. An indwelling
catheter was placed in the bilateral internal iliac artery, and
the pump was placed in a subcutaneous pocket in February
2005. The combination chemotherapy consisted of CDDP
(20 mg/m2) (days 1–5) and IFM (1.2 mg/m2) (days 1–3),
and its regimen cycle was every 21 days. The patient
received two courses of chemotherapy, after which his PSA
value decreased to 1.94 ng/ml, the tumor showed a
remarkable reduction in size (Fig. 2), and the symptom
improved. In this case, grade 3 neutropenia (which was
improved by granulocyte-colony stimulating factor), vom-
iting, general fatigue, and grade 3 alopecia were observed.
However, other serious side effects that could pose a risk to
continued intra-arterial infusion chemotherapy were not
observed. Therefore, we were able to continue chemother-
apy according to schedule. However, PSA value gradually
increased to 4.61 ng/ml in April 2006. We once again
attempted intra-arterial infusion chemotherapy of CDDP
and IFM with the same dose as previously used (Fig. 3).
At a later time, the PSA value once again rose from the
value in May 2007. However, the patient had no symptoms
of LUTS for 45 months after the ﬁrst chemotherapy
treatment.
Discussion
Treating HRPC is troublesome for a urologist because
the standard treatment has not yet been established.
Fig. 1 Magnetic resonance imaging (MRI) shows anastomotic
recurrence after radical prostatectomy and radiation therapy
Fig. 2 Magnetic resonance imaging (MRI shows disappearance of
the anastomotic tumor after intra-arterial infusion chemotherapy
Fig. 3 Progress of PSA treatment and transition values
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The prognosis of patients with HRPC is commonly thought
to be unfavorable [1]. In addition, HRPC patients occa-
sionally have LUTS, such as urinary retention and dysuria
accompanied with gross hematuria, which adversely affects
quality of life. Here, we reported a case of urinary retention
due to locally recurrent HRPC in which retention was
improved by intra-arterial infusion of CDDP and IFM.
According to the established criteria for evaluating out-
comes of nonsurgical therapy for prostate cancer, the
prostatic lesions of the case showed a partial response (PR).
However, on the basis of PSA responses, the patient
showed complete response (CR).
At present, HRPC treatments, such as antiandrogen
alteration, systemic chemotherapy with DTX [3, 4], and
low-dose steroids [2], are effective in the short term, but
their effectiveness decreases over time. Various general-
ized combination chemotherapies have been tried for
HRPC, but no reports of their long-term efﬁcacy are
available [5–10]. In the 1990s, intra-arterial chemothera-
pies for HRPC were reported, which indicated that,
whereas they were effective for local carcinostatics, they
were not effective as a generalized treatment modality
[11–13]. In the study reported here, because we encountered
locally recurring HRPC with LUTS, we thought it may be
worthwhile to try intra-arterial chemotherapy for relieving
LUTS caused by HRPC. Our cases suggest that intra-
arterial chemotherapy may be a good choice for treating
HRPC with locally recurring HRPC only. However, the
problem with this therapy is that it does not radically treat
the cancer. In addition, it should not be administered in
cases with poor performance status or prognosis. DTX
could be used as a second-line intra-arterial chemotherapy
treatment after CDDP and IFM, because intra-arterial DTX
accompanied with CDDP for oropharyngeal cancer is
reported to result in an excellent primary response rate and
acceptable acute toxicity [14].
In conclusion, intra-arterial chemotherapy with CDDP
and IFM can alleviate LUTS caused by locally recurrent
HRPC. Furthermore, this therapy could maintain patients’
quality of life for relatively long periods. Accordingly, this
regimen should be seen as a treatment option for locally
recurrent HRPC. As the number of prostate cancer cases
increases, urologists are likely to encounter more patients
who are suitable for such treatment.
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